Northern Colorado COVID-19 Biobank

Conditions

Covid19

Keywords

biobank, biorepository, SARS-CoV-2 infection, COVID-19, coronavirus

Brief summary

The NoCo-CoBio Project is a biobanking effort to store and preserve saliva, nasopharyngeal, stool and blood specimens from SARS-CoV-2 PCR (polymerase chain reaction) positive individuals.

Detailed description

The investigators have created a biorepository of stool, saliva, nasopharyngeal swab specimens, peripheral blood mononuclear cells, serum, and plasma from SARS-CoV-2 infected individuals for research purposes. The multifaceted biorepository will be used to establish markers predicting various presentations of COVID-19 (coronavirus disease 2019).

Whitcomb LA, Berry K, LaVergne SM, Natter N, Baxter BA, Rao S, Tipton M, Gritsenko MA, Weitz KK, Gerbasi V, Bramer LM, Piehowski PD, Webb TL, Henao-Tamayo M, Chicco AJ, Dunn J, Dutt TS, Ryan EP.

2025-12-10

10.1186/s12879-025-11824-3

Relationships between plasma fatty acids in adults with mild, moderate, or severe COVID-19 and the development of post-acute sequelae

Sophia Stromberg, Bridget A. Baxter, Gregory Dooley, Stephanie M. LaVergne, Emily N. Gallichotte et al. (17 authors)

Frontiers in Nutrition2022-09-1413 citations

10.3389/fnut.2022.960409

A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.

LaVergne SM, Stromberg S, Baxter BA, Webb TL, Dutt TS, Berry K, Tipton M, Haberman J, Massey BR, McFann K, Alnachoukati O, Zier L, Heacock T, Ebel GD, Henao-Tamayo M, Dunn J, Ryan EP.

2021-07-1342 citations

10.1186/s12879-021-06359-2

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Those who have had a positive SARS-CoV-2 PCR test

Exclusion criteria

* under 18 years of age * pregnant

Design outcomes

Primary

Measure	Time frame	Description
Evaluation of parameters for markers of SARS-CoV-2 infection and predictors for severe disease	6 months	Evaluation of parameters for markers of SARS-CoV-2 infection and predictors for severe disease

Secondary

Measure	Time frame	Description
Evaluation of markers and predictors of post acute sequelae of COVID-19	2 years	Evaluation of markers and predictors of post acute sequelae of COVID-19

Countries

United States

Outcome results